Skip to main content
4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc. — Investor Relations & Filings

Ticker · FDMT ISIN · US35104E1001 US Manufacturing
Open in API
Filings indexed 372 across all filing types
Latest filing 2026-05-07 Capital/Financing Update
Country US United States of America
Listing US FDMT

About 4D Molecular Therapeutics, Inc.

https://4dmoleculartherapeutics.com/

4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on inventing and developing genetic medicines to treat large-market diseases with unmet medical needs. The company utilizes its proprietary Therapeutic Vector Evolution platform, which harnesses the power of directed evolution, to create customized and optimized adeno-associated virus (AAV) vectors. These engineered vectors are designed for targeted delivery and enhanced therapeutic efficacy. 4DMT's clinical pipeline is concentrated on developing transformative products for serious conditions in ophthalmology, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), and in pulmonology, including cystic fibrosis.

Recent filings

Filing Released Lang Actions
S-3 - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
Capital/Financing Update Classification · 85% confidence The document is an SEC Form S-3 registration statement and prospectus outlining the terms and conditions for a shelf offering of up to $400 million in common stock, preferred stock, debt securities, warrants, and units. It contains detailed sections on risk factors, use of proceeds, descriptions of securities, plan of distribution and legal matters, all of which support a primary focus on financing activities. This aligns with the Capital/Financing Update category (CAP).
2026-05-07 English
SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
Major Shareholding Notification
2026-03-26 English
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
Director's Dealing
2026-03-24 English
8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company announced its financial results for the year ended December 31, 2025, via a press release attached as Exhibit 99.1. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release. The length is 3208 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces or furnishes a press release of financial results without containing the full financial data should be classified as a Regulatory Filing (RNS), as it does not meet the criteria for an Earnings Release (ER) or Annual Report (10-K).
2026-03-18 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.